ARTICLE | Financial News
Actelion spinout Idorsia to list next week
June 9, 2017 11:39 PM UTC
On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson & Johnson (NYSE:JNJ) is acquiring in a deal expected to close on the same date.
Current Actelion CEO Jean-Paul Clozel will be Idorsia's CEO. The J&J deal values Actelion at $30 billion (see BioCentury, Feb. 3 & BioCentury, May 26)...